NeoGenomics Reports $186.7 Million Revenue in Q1 2026, Up 11.1%

NeoGenomics, Inc. reported a net revenue of $186.7 million for the first quarter of 2026, marking an increase of 11.1% from $168.0 million in the same period of 2025. The growth in revenue was attributed to higher test volumes, a shift towards more valuable tests, and successful reimbursement initiatives. The company also benefited from contributions from its recent acquisition of Pathline, although this was partially offset by a decline in non-clinical revenue due to trends in the pharmaceutical industry.

The cost of revenue for the quarter rose to $105.8 million, up 11.6% from $94.8 million a year earlier, primarily driven by increased expenses in supplies, compensation, and shipping. As a result, gross profit increased to $80.9 million, with a gross profit margin of 43.3%, slightly down from 43.6% in the previous year. Operating expenses decreased to $99.1 million from $101.1 million, leading to a reduced loss from operations of $18.2 million compared to $27.8 million in the prior year. The net loss for the quarter was $17.1 million, or $(0.13) per share, an improvement from a net loss of $25.9 million, or $(0.20) per share, in the same quarter of 2025.

In terms of strategic developments, NeoGenomics completed the acquisition of Pathline, a laboratory based in New Jersey, in April 2025, which is expected to enhance its capabilities and market presence in the Northeastern United States. The company also sold its subsidiary Trapelo Health at the end of 2025, which resulted in a significant impairment charge in the previous fiscal year but did not affect the current quarter's results. The company continues to focus on expanding its oncology diagnostic testing services and enhancing its product offerings.

Operationally, NeoGenomics reported a slight increase in customer engagement, with a focus on expanding its market share in community oncology. The company operates multiple laboratories across the U.S. and the U.K., and it aims to leverage its existing infrastructure to drive growth. As of March 31, 2026, NeoGenomics had $146.1 million in cash and cash equivalents, which it expects to be sufficient to meet its operational needs for at least the next 12 months.

Looking ahead, NeoGenomics plans to continue investing in research and development to innovate and bring new tests to market. The company is also focused on optimizing its customer experience and operational efficiency, with an emphasis on automation and process improvements. Management anticipates that these initiatives will support sustained growth and enhance its position as a leader in cancer testing and diagnostics.